{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:23:18Z","timestamp":1776090198967,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12325-020-01613-6","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T19:03:20Z","timestamp":1611515000000},"page":"2213-2225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-1425","authenticated-orcid":false,"given":"Sarah S.","family":"Mougalian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan K.","family":"Kish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingchuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djibril","family":"Liassou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,24]]},"reference":[{"issue":"6","key":"1613_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","volume":"26","author":"AB Mariotto","year":"2017","unstructured":"Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809\u201315.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1613_CR2","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer Subtypes. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed 4 June 2020."},{"issue":"4","key":"1613_CR3","doi-asserted-by":"publisher","first-page":"pky062","DOI":"10.1093\/jncics\/pky062","volume":"2","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2(4):pky062.","journal-title":"JNCI Cancer Spectr."},{"key":"1613_CR4","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html Accessed 4 June 2020."},{"issue":"6","key":"1613_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, et al. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomark Prev. 2018;27(6):619\u201326.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1613_CR6","unstructured":"Eisai Incorporated. Halaven\u00a0(eribulin mesylate) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/201532lbl.pdf Revised November 2010. Accessed 9 July 2020."},{"issue":"9769","key":"1613_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914\u201323.","journal-title":"Lancet"},{"key":"1613_CR8","doi-asserted-by":"publisher","first-page":"175883591989575","DOI":"10.1177\/1758835919895755","volume":"11","author":"V Adamo","year":"2019","unstructured":"Adamo V, Ricciardi GRR, Giuffrida D, et al. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. Ther Adv Med Oncol. 2019;11:1758835919895755.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"1613_CR9","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1002\/ijc.32402","volume":"145","author":"W Jacot","year":"2019","unstructured":"Jacot W, Heudel PE, Fraisse J, et al. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int J Cancer. 2019;145(12):3359\u201369.","journal-title":"Int J Cancer"},{"issue":"5","key":"1613_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s10637-019-00890-5","volume":"38","author":"K Inoue","year":"2020","unstructured":"Inoue K, Takahashi M, Mukai H, et al. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. 2020;38(5):1540\u20139.","journal-title":"Invest New Drugs."},{"issue":"2","key":"1613_CR11","doi-asserted-by":"publisher","first-page":"e000176","DOI":"10.1136\/esmoopen-2017-000176","volume":"2","author":"M Orditura","year":"2017","unstructured":"Orditura M, Gravina A, Riccardi F, et al. Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial). ESMO Open. 2017;2(2):e000176.","journal-title":"ESMO Open"},{"issue":"1","key":"1613_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2217\/fon-2018-0324","volume":"15","author":"S Barni","year":"2019","unstructured":"Barni S, Livraghi L, Morritti M, et al. Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study. Future Oncol. 2019;15(1):33\u201344.","journal-title":"Future Oncol"},{"issue":"9","key":"1613_CR13","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1002\/cam4.1705","volume":"7","author":"SS Mougalian","year":"2018","unstructured":"Mougalian SS, Copher R, Kish JK, et al. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting. Cancer Med. 2018;7(9):4371\u20138.","journal-title":"Cancer Med"},{"issue":"34","key":"1613_CR14","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.2217\/fon-2019-0537","volume":"15","author":"SS Mougalian","year":"2019","unstructured":"Mougalian SS, Feinberg BA, Wang E, et al. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4\/6 inhibitor therapy. Future Oncol. 2019;15(34):3935\u201344.","journal-title":"Future Oncol"},{"key":"1613_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/EDBK_156686","volume":"35","author":"JM Unger","year":"2016","unstructured":"Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185\u201398.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"1613_CR16","doi-asserted-by":"publisher","first-page":"dju002","DOI":"10.1093\/jnci\/dju002","volume":"106","author":"JM Unger","year":"2014","unstructured":"Unger JM, Barlow WE, Martin DP, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014;106(3):dju002.","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"1613_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1634\/theoncologist.2019-0699","volume":"25","author":"B Feinberg","year":"2020","unstructured":"Feinberg B, Kish J, Dokubo I, Wojtynek J, Gajra A, Lord K. Comparative effectiveness of palliative chemotherapy in metastatic breast cancer: a real-world evidence analysis. Oncologist. 2020;25(4):319\u201326.","journal-title":"Oncologist"},{"issue":"6","key":"1613_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594\u2013601.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1613_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/CAD.0000000000000493","volume":"28","author":"IA Voutsadakis","year":"2017","unstructured":"Voutsadakis IA. A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer. Anticancer Drugs. 2017;28(5):557\u201364.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"1613_CR20","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1080\/03007995.2020.1835853","volume":"36","author":"I Chabot","year":"2020","unstructured":"Chabot I, Zhao Q, Su Y. Systematic review of real-world effectiveness of eribulin for locally advanced or metastatic breast cancer. Curr Med Res Opin. 2020;36(12):2025\u201336.","journal-title":"Curr Med Res Opin."},{"issue":"9","key":"1613_CR21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","volume":"21","author":"P Sharma","year":"2016","unstructured":"Sharma P. Biology and management of patients with triple-negative breast cancer. Oncologist. 2016;21(9):1050\u201362.","journal-title":"Oncologist"}],"updated-by":[{"DOI":"10.1007\/s12325-021-01780-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000}},{"DOI":"10.1007\/s12325-021-01683-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01613-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T12:41:49Z","timestamp":1627648909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01613-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,24]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01613-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-021-01780-0","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s12325-021-01683-0","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,24]]},"assertion":[{"value":"1 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-021-01683-0","URL":"https:\/\/doi.org\/10.1007\/s12325-021-01683-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2021","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-021-01780-0","URL":"https:\/\/doi.org\/10.1007\/s12325-021-01780-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}